Posts Tagged ‘encodec’

Sequence of events in prostate cancer

October 5, 2018

Sequence of events in prostate #cancer, by @MarkARubin1 Discusses the high prevalence of AR-enhancer amplifications in recent studies
“Quigley and colleagues performed whole-genome sequencing of 101 samples of metastatic, castration-resistant prostate-cancer tissue obtained from previous studies11,12. The most frequently altered genomic site identified was the AR-enhancer region, which was amplified in 81% of samples. The high prevalence of this type of amplification is notable because enhancer amplifications identified so far for other cancer types generally arise at much lower
frequency13–16. Moreover, the high prevalence of this AR-enhancer amplification in the data presented by Viswanathan and Quigley contrasts with its occurrence in only 1 of 54 previously published whole-genome sequences of prostate-cancer samples obtained before clinical treatment had commenced17.”

New study finds cell line difference across labs

August 16, 2018
“… comprehensive genomic characterization of 27 strains of the common breast cancer cell line MCF7 uncovered rapid genetic
diversification. Similar results were obtained with multiple strains of 13 additional cell lines.

genome-wide starr-seq + sources of experimental bias

August 12, 2018

quite relevant

Resolving systematic errors in widely used enhancer activity assays in human cells

Felix Muerdter
, Łukasz M Boryń
, Ashley R Woodfin
, Christoph Neumayr
, Martina Rath
, Muhammad A Zabidi
, Michaela Pagani
, Vanja Haberle
, Tomáš Kazmar
, Rui R Catarino
, Katharina Schernhuber
, Cosmas D Arnold
& Alexander Stark

Nature Methods volume 15, pages141–149 (2018)

The Cancer Genome Atlas: Creating Lasting Value beyond Its Data

June 15, 2018

The Cancer Genome Atlas: Creating Lasting Value beyond Its Data Carolyn Hutter + Jean Claude Zenklusen

Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies – ScienceDirect

April 28, 2018

Genome-Scale Signatures of Gene Interaction from #CompoundScreens Predict…Efficacy of Targeted Cancer Therapies How to find drug combos: Find expression response profiles associated w/ a drug target. A synergistic drug might change profiles similarly

ncdriver and ENCODE

March 17, 2018

Received: 13 November 2017 Revised: 22 November 2017 Accepted: 29 November 2017

Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma | Nature Genetics

February 11, 2018

Chromatin states define tumour-specific T cell dysfunction and reprogramming | Nature

November 19, 2017

STAR Methods

September 28, 2017

Here is the STAR Methods format (Structured, Transparent, Accessible Reporting) introduced last year by Cell, marketed as a structure that “promotes transparent reporting of experimental design and
methodological details.” Details are in the links below.

Editorial: Instructions:

US cancer institute to overhaul tumour cell lines

July 9, 2017

“The NCI will continue to supply the NCI-60 cell lines to researchers, but will eventually refocus its drug screening on newer models. It is developing hundreds of ‘patient-derived xenografts’ (PDXs), which are created by implanting small chunks of human tumours into mice. There, the tumours grow in an environment that, although not human, better mimics their native environment”